Welcome to Roche HIV website
Latest News
ROCHE ANNOUNCES FIRST RESULTS OF PROMISING NEW PROTEASE INHIBITOR AGAINST RESISTANT HIV
17-Feb-03
ROCHE UPDATES PRICING POLICY FOR PROTEASE INHIBITOR AIDS DRUGS WITHIN ACCELERATING ACCESS INITIATIVE
13-Feb-03
UPDATE ON THE MANUFACTURE OF NEW HIV DRUG FUZEON
18-Dec-02
ROCHE RECEIVES FDA CLEARANCE FOR THE COBAS AMPLISCREEN SYSTEM
05-Dec-02
ROCHE RESPONSE TO MSF LETTER
18-Nov-02
NEW DATA INDICATE TREATMENT OF HIV WITH FUZEON SHOULD BE INITIATED BEFORE ALL OTHER TREATMENT OPTIONS DEPLETED
18-Nov-02
FUZEON (ENFUVIRTIDE, T-20) DEMONSTRATES CONSISTENT BENEFIT ACROSS RANGE OF TREATMENT EXPERIENCED HIV PATIENTS
30-Sep-02
REGULATORY FILING IN EUROPEAN UNION FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20)
20-Sep-02
EUROPEAN COMMISSION APPROVES NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR TWICE DAILY)
19-Sep-02
REGULATORY FILING FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20)
17-Sep-02
ROCHE AND TRIMERIS ANNOUNCE NEXT STEPS IN BRINGING FUZEON (T-20) TO HIV PATIENTS IN NEED OF NEW TREATMENT OPTIONS
02-Aug-02
U.S. FOOD AND DRUG ADMINISTRATION APPROVES NEXT GENERATION HIV-1 TEST
01-Aug-02
FIRST HEAD-TO-HEAD STUDY OF TWO BOOSTED PROTEASE INHIBITORS SHOWS SIGNIFICANT BENEFIT FOR BOOSTED SAQUINAVIR REGIMEN
10-Jul-02
NEW BOOSTED SAQUINAVIR DOSING (1000 MG SAQUINAVIR PLUS 100 MG RITONAVIR BID ) MAINTAINS HIV SUPPRESSION WHILE REDUCING TRIGLYCERIDES AND CHOLESTEROL
10-Jul-02
MAJORITY OF HIV PATIENTS FIND NEW INJECTABLE FUSION INHIBITOR T-20 (ENFUVIRTIDE) EASY TO USE
09-Jul-02
RESEARCHERS IDENTIFY PREDICTIVE AND CLINICAL VALUE OF PROVIRAL HIV-1 DNA QUANTIFICATION FOR HIV PATIENTS
09-Jul-02
NEW T-20 (ENFUVIRTIDE) RESEARCH SIGNALS NEW HOPE FOR CHILDREN AND ADOLESCENTS LIVING WITH HIV
09-Jul-02
FOUR STUDIES EXAMINE STRATEGY OF COMBINING SAQUINAVIR WITH KALETRA® IN TREATMENT-EXPERIENCED HIV PATIENTS
09-Jul-02
TREATMENT EXPERIENCED PATIENTS TWICE AS LIKELY TO ACHIEVE UNDETECTABLE HIV LEVELS WITH T-20 (ENFUVIRTIDE) THAN WITHOUT
08-Jul-02
ROCHE RENEWS ITS COMMITMENT TO THE MULTICENTER AIDS COHORT STUDY
08-Jul-02
ROCHE DIAGNOSTICS SPONSORS SURVEILLANCE PROGRAM TO HELP ENSURE FUTURE PERFORMANCE OF INDUSTRY’S HIV VIRAL LOAD ASSAYS
02-Jul-02
NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR BID) TO TREAT HIV RECEIVES CPMP POSITIVE OPINION IN THE EU
19-Jun-02
POSITIVE RESULTS FROM SECOND PHASE III STUDY OF HIV FUSION INHIBITOR T-20 (ENFUVIRTIDE)
16-May-02
ROCHE AND TRIMERIS ANNOUNCE 24-WEEK RESULTS FROM FIRST PHASE III STUDY OF HIV FUSION INHIBITOR T-20
18-Apr-02
NEW PROMISING DRUG ADDED TO ROCHE’S STRONG HIV PORTFOLIO
15-Apr-02
STUDY PUBLISHED IN TODAY'S New England Journal of Medicine CONFIRMS ORAL VALCYTE™ TREATS AIDS-RELATED EYE DISEASE AS WELL AS IV GANCICLOVIR THERAPY
11-Apr-02
VALCYTE™ RECEIVES EU POSITIVE OPINION FOR TREATMENT OF AIDS-RELATED CMV RETINITIS
13-Mar-02
NEW EVIDENCE THAT T-20 ADDS POTENCY TO CONVENTIONAL HIV THERAPIES
19-Feb-02
START OF PILOT PROGRAMME MAY LEAD TO A NEW ERA IN HEALTHCARE DELIVERY FOR AFRICA'S DEVELOPING COUNTRIES
14-Jan-02